Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 10:59 PM
Ignite Modification Date: 2025-12-25 @ 8:28 PM
NCT ID: NCT03686969
Description: Number of patients at risk for SAEs, All-Cause Mortality, and other adverse events in placebo group is 0 as 0 patients were enrolled into the placebo group.
Frequency Threshold: 0
Time Frame: The patient was treated according to the protocol until week 14 Treatment after week 14 was discontinued because of early study termination
Study: NCT03686969
Study Brief: Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Octanorm 0.5g/kg/week octanorm 16.5% Octanorm: Octanorm 0.5g/kg/week 0 None 0 1 1 1 View
Placebo Placebo Placebo: Placebo 0 None 0 0 0 0 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dermatomyositis SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (Unspecified) View
Infusion site haematoma SYSTEMATIC_ASSESSMENT General disorders MedDRA (Unspecified) View
Blood lactate dehydrogenase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Blood creatine phosphokinase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View
Aldolase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (Unspecified) View